1. Home
  2. OMER vs SFIX Comparison

OMER vs SFIX Comparison

Compare OMER & SFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OMER
  • SFIX
  • Stock Information
  • Founded
  • OMER 1994
  • SFIX 2011
  • Country
  • OMER United States
  • SFIX United States
  • Employees
  • OMER N/A
  • SFIX N/A
  • Industry
  • OMER Biotechnology: Pharmaceutical Preparations
  • SFIX Catalog/Specialty Distribution
  • Sector
  • OMER Health Care
  • SFIX Consumer Discretionary
  • Exchange
  • OMER Nasdaq
  • SFIX Nasdaq
  • Market Cap
  • OMER 397.1M
  • SFIX 394.1M
  • IPO Year
  • OMER 2009
  • SFIX 2017
  • Fundamental
  • Price
  • OMER $3.22
  • SFIX $4.21
  • Analyst Decision
  • OMER Buy
  • SFIX Hold
  • Analyst Count
  • OMER 4
  • SFIX 6
  • Target Price
  • OMER $22.50
  • SFIX $4.50
  • AVG Volume (30 Days)
  • OMER 1.2M
  • SFIX 1.6M
  • Earning Date
  • OMER 05-15-2025
  • SFIX 06-03-2025
  • Dividend Yield
  • OMER N/A
  • SFIX N/A
  • EPS Growth
  • OMER N/A
  • SFIX N/A
  • EPS
  • OMER N/A
  • SFIX N/A
  • Revenue
  • OMER N/A
  • SFIX $1,273,209,000.00
  • Revenue This Year
  • OMER N/A
  • SFIX N/A
  • Revenue Next Year
  • OMER $2,447.88
  • SFIX N/A
  • P/E Ratio
  • OMER N/A
  • SFIX N/A
  • Revenue Growth
  • OMER N/A
  • SFIX N/A
  • 52 Week Low
  • OMER $3.00
  • SFIX $2.06
  • 52 Week High
  • OMER $13.60
  • SFIX $6.99
  • Technical
  • Relative Strength Index (RSI)
  • OMER 23.29
  • SFIX 66.35
  • Support Level
  • OMER $3.79
  • SFIX $4.14
  • Resistance Level
  • OMER $6.58
  • SFIX $4.59
  • Average True Range (ATR)
  • OMER 0.59
  • SFIX 0.22
  • MACD
  • OMER -0.33
  • SFIX 0.13
  • Stochastic Oscillator
  • OMER 5.43
  • SFIX 73.05

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

About SFIX Stitch Fix Inc.

Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.

Share on Social Networks: